


**Product Name** : BRD0705  
**Cat. No.** : PC-63311  
**CAS No.** : 2056261-41-5  
**Molecular Formula** : C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O  
**Molecular Weight** : 321.424  
**Target** : GSK-3  
**Solubility** : 10 mM in DMSO



### Biological Activity

BRD0705 (BRD-0705) is a potent, paralog-selective **GSK3 $\alpha$**  inhibitor with IC<sub>50</sub> of 66 nM, 8-fold selectivity over GSK3 $\beta$  (IC<sub>50</sub>=515 nM).

BRD0705 displays excellent selectivity in a panel of 311 kinases, the CDK family of CDK2, CDK3 and CDK5) are most potently inhibited with IC<sub>50</sub> of 6.87, 9.74 and 9.20  $\mu$ M (87-, 123-, and 116-fold selectivity relative to GSK3 $\alpha$ ).

BRD0705 inhibits GSK3 $\alpha$  kinase function, impairs GSK3 $\alpha$  Tyr279 phosphorylation in a time- and concentration-dependent manner without affecting GSK3 $\beta$  Tyr216 phosphorylation, and does not stabilize  $\beta$ -catenin, induces myeloid differentiation and impairs colony formation in AML cells, with no apparent effect on normal hematopoietic cells.

BRD0705 impairs leukemia initiation and prolongs survival in AML mouse models.

### References

Wagner FF, et al. *Sci Transl Med*. 2018 Mar 7;10(431). pii: eaam8460.

*Cancer Discov*. 2018 Mar 16. doi: 10.1158/2159-8290.CD-RW2018-046.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com